Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation

Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022) · Perfusion · n=1232

RCT evidence detailTrial reference

GRADE LowCohort / case seriesCondition: Venous Congestion in Surgical Flaps →

This trial (highlighted) by sample size alongside other indexed Venous Congestion in Surgical Flaps trials. Larger trials generally carry more statistical weight.

Study Profile

Design: systematic review and meta-analysis of 12 retrospective cohort studies through April 2022 (PubMed, Embase, Cochrane Library)
Sample size (n): 1232
Intervention: Bivalirudin anticoagulation for ECMO (n=497 across pooled cohorts)
Comparator: Unfractionated heparin anticoagulation (n=735)
Primary endpoint: In-hospital mortality (short-term death)
Primary result: No significant difference in mortality (RR 0.95, 95% CI 0.79-1.13, p=0.546) or thrombotic events (RR 0.78, 95% CI 0.45-1.35); bivalirudin significantly reduced bleeding events (RR 0.48, 95% CI 0.25-0.95, p=0.035)
Follow-up duration: Hospital discharge
PMID: 35616224

Key Findings

Largest contemporary pooled dataset (n=1,232) on ECMO anticoagulation choice
Equivalent mortality between bivalirudin and heparin
Equivalent thrombotic event rates
Bivalirudin associated with reduced bleeding complications (52% relative reduction)
Highlights need for prospective RCTs

Limitations

All included studies were retrospective observational
Significant clinical heterogeneity across centers
Publication bias likely
Patient selection bias - sicker patients more likely to receive bivalirudin
Not applicable to whole-leech hirudotherapy

Clinical Implications

Huang 2022 is a foundational evidence synthesis for ECMO anticoagulation choice. For ASH, the meta-analysis demonstrates how the synthetic hirudin-derivative pathway operates under retrospective observational evidence with bleeding-reduction signal but no mortality benefit. This evidence base is structurally distinct from the device-leech K040187 US practice and serves as a reference for the broader hirudin-derived anticoagulant landscape.

Related Trials

Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation

McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)

Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support

Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)

Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review

Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)

Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation

Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Keaton B, Acquah SO, Im Lee Y (2022)

← Back to RCT Library